Pernod completes sale of wine portfolio to Accolade Wines owner
Pernod Ricard sold its international wine portfolio to Accolade Wines. This could enhance Accolade's market position and growth prospects.
View signal analysisCompany intelligence
ACCD
Accolade, Inc. · NASDAQ · Healthcare
Price$7.02+0.00% · +$0.00
Market cap575.59MEquity value
P / E-3.1Trailing ratio
Volume4.54MLatest session
Market data
TradingViewACCD price chart
Related signals
1 min delayedLatest ACCD price-moving signals
Browse public ACCD signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Digital health startup Transcarent takes Accolade private in $621 million deal
Transcarent acquires Accolade for $621 million, enhancing offerings. Accolade shares now valued at $7.03 each, no longer traded. Acquisition completed amid resilience challenges in digital health sector. Transcarent secured funding and previously earned accolades as a disruptor. Accolade's public market exit reflects ongoing struggles in digital health.
View signal analysisWhy Is Accolade Stock Trading Over 100% On Tuesday?
Transcarent to acquire Accolade for $621 million, $7.03 per share. Transaction represents a 110% premium over Accolade’s last closing price. Merger aims to improve healthcare outcomes via enhanced personalized experiences. New platform combines Accolade’s and Transcarent’s healthcare expertise and AI tools. Accolade's stock surged 104.7% to $6.86 following acquisition news.
View signal analysisResearch